Assessing the potential impact of non-proprietary drug copies on quality of medicine and treatment in patients with relapsing multiple sclerosis: the experience with fingolimod

by Correale J, Chiquete E, Milojevic S, Frider N, Bajusz I
Published 2014-06-01

Clinical implications for substandard, nonproprietary medicines in multiple sclerosis: focus on fingolimod

by Correale J, Chiquete E, Boyko A, Beran RG, Strauch JB, Milojevic S, Frider N
Published 2016-06-01